Advaxis, Inc. (NASDAQ:ADXS) had its Hold ➝ Neutral rating reiterated by HC Wainwright

Advaxis, Inc. (NASDAQ:ADXS) had its Hold ➝ Neutral rating reiterated by HC Wainwright

Jun 12, 2019 (Market Exclusive via COMTEX) —

Analyst Ratings For Advaxis, Inc. (NASDAQ:ADXS)

Today, HC Wainwright reiterated its Hold rating on Advaxis, Inc. (NASDAQ:ADXS).

There are 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings, no Buy Ratings on the stock.

The current consensus rating on Advaxis, Inc. (NASDAQ:ADXS) is Hold with a consensus target price of $3.00 per share, a potential 17.65% upside.

Some recent analyst ratings include

6/12/2019-Advaxis, Inc. (NASDAQ:ADXS) had its Hold ➝ Neutral rating reiterated by HC Wainwright 6/13/2018-Advaxis, Inc. (NASDAQ:ADXS) gets downgraded to Hold by Jefferies Financial Group with a price target of $2.00 On 4/10/2019 Roni Appel, Director, bought 3,000 with an average share price of $3.80 per share and the total transaction amounting to $11,400.00. On 11/5/2018 Robert Petit, Insider, sold 3,963 with an average share price of $0.58 per share and the total transaction amounting to $2,298.54. On 11/2/2018 Robert Petit, Insider, sold 8,491 with an average share price of $0.56 per share and the total transaction amounting to $4,754.96. On 9/11/2018 Roni Appel, Director, bought 33,333 with an average share price of $1.20 per share and the total transaction amounting to $39,999.60. On 4/2/2018 Robert Petit, Insider, sold 2,193 with an average share price of $1.62 per share and the total transaction amounting to $3,552.66. On 2/2/2018 Anthony A Lombardo, CEO, sold 32 with an average share price of $2.93 per share and the total transaction amounting to $93.76. On 1/3/2018 Sara Bonstein, CFO, sold 5,224 with an average share price of $3.18 per share and the total transaction amounting to $16,612.32.

About Advaxis, Inc. (NASDAQ:ADXS)
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based

Read More Here...

Bookmark the permalink.